What is claimed is:

1. A pharmaceutical composition comprising:

at least one compound chosen from 2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile and pharmaceutically acceptable salts thereof; and

at least one pH dependent gelling agent,

wherein the pharmaceutical composition is in the form of a gel.

2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises about 0.1% to about 4% by weight of the at least one pH dependent gelling agent.

3. The pharmaceutical composition of claim 1 or 2, wherein the at least one pH dependent gelling agent is Carbopol® 980 polymer.

4. The pharmaceutical composition of any one of claims 1-3, wherein the at least one compound is suspended in the gel.

5. The pharmaceutical composition of any one of claims 1-4, further comprising at least one emollient or humectant.

6. The pharmaceutical composition of claim 5, wherein the pharmaceutical composition comprises about 0.1% to about 65% by weight of the at least one emollient or humectant.

7. The pharmaceutical composition of claim 5 or 6, wherein the at least one emollient or humectant is chosen from glycerin, propylene glycol, and combinations thereof.

8. The pharmaceutical composition of any one of claims 1-7, further comprising at least one preservative.

9. The pharmaceutical composition of claim 8, wherein the pharmaceutical composition comprises about 0.01% to about 0.7% by weight of the at least one preservative.

10. The pharmaceutical composition of claim 8 or 9, wherein the at least one preservative is chosen from methylparaben, propylparaben, and combinations thereof.

11. The pharmaceutical composition of any one of claims 1-10, further comprising at least one lubricity agent.

12. The pharmaceutical composition of claim 11, wherein the pharmaceutical composition comprises about 0.1% to about 20% by weight of the at least one lubricity agent.

13. The pharmaceutical composition of claim 11 or 12, wherein the at least one lubricity agent is chosen from medium chain triglycerides.

14. The pharmaceutical composition of any one of claims 1-13, further comprising at least one wetting agent.

15. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises about 0.1% to about 20% by weight of the at least one wetting agent.

16. The pharmaceutical composition of claim 14 or 15, wherein the at least one wetting agent is polysorbate 80.

17. The pharmaceutical composition of any one of claims 1-16, further comprising at least one vehicle.

18. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises:

about 0.1% to about 20% by weight of medium chain triglycerides;
about 0.1% to about 20% by weight of Polysorbate 80;
about 0.1% to about 20% by weight of glycerin;
about 0.1% to about 45% by weight of propylene glycol;
about 0.01% to about 0.5% by weight of methylparaben;
about 0.01% to about 0.2% by weight of propylparaben;
about 0.1% to about 4% by weight of Carbopol® 980 polymer;

an amount of 10% (w/w) sodium hydroxide solution sufficient to adjust the pH of the pharmaceutical composition to a value in the range of about 4 to about 6; and

Q.S. to 100 of purified water.

19. A pharmaceutical composition comprising:

at least one compound chosen from 2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile and pharmaceutically acceptable salts thereof; and

at least one saturated hydrocarbon,

wherein the pharmaceutical composition is in the form of an ointment.

20. The pharmaceutical composition of claim 19, wherein the at least one saturated hydrocarbon is chosen from mineral oil, hydrogenated castor oil, and combinations thereof.

21. The pharmaceutical composition of claim 19 or 20, wherein the at least one compound is suspended in the ointment.

22. The pharmaceutical composition of any one of claims 19-21, further comprising at least one viscosity modifier.

23. The pharmaceutical composition of claim 22, wherein the pharmaceutical composition comprises about 0.1% to about 20% by weight of the at least one viscosity modifier.

24. The pharmaceutical composition of claim 22 or 23, wherein the at least one viscosity modifier is microcrystalline wax.

25. The pharmaceutical composition of any one of claims 19-24, further comprising at least one dispersing agent.

26. The pharmaceutical composition of claim 25, wherein the pharmaceutical composition comprises about 0.01% to about 30% by weight of the at least one dispersing agent.

27. The pharmaceutical composition of claim 25 or 26, wherein the at least one dispersing agent is chosen from dimethicone, medium chain triglycerides, and combinations thereof.

28. The pharmaceutical composition of claim 19, wherein the pharmaceutical composition comprises:

about 0.1% to about 20% by weight of medium chain triglycerides;

about 0.1% to about 20% by weight of microcrystalline wax;

about 0.1% to about 10% by weight of hydrogenated castor oil;

about 0.01% to about 10% by weight of dimethicone; and

Q.S. to 100 of white mineral oil.

29. A pharmaceutical composition comprising:

at least one compound chosen from 2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile and pharmaceutically acceptable salts thereof; and

at least one dissolution agent,

wherein the pharmaceutical composition is in the form of a cream.

30. The pharmaceutical composition of claim 29, wherein the pharmaceutical composition comprises about 1% to about 45% by weight of the at least one dissolution agent.

31. The pharmaceutical composition of claim 29 or 30, wherein the at least one dissolution agent is oleic acid.

32. The pharmaceutical composition of any one of claims 29-31, wherein the at least one compound is dissolved in the cream.

33. The pharmaceutical composition of any one of claims 29-32, further comprising at least one gelling-emulsifier.

34. The pharmaceutical composition of claim 33, wherein the pharmaceutical composition comprises about 0.1% to about 5% by weight of the at least one gelling-emulsifier.

35. The pharmaceutical composition of claim 33 or 34, wherein the at least one gelling-emulsifier is Pemulen™ TR-1.

36. The pharmaceutical composition of any one of claims 29-35, further comprising at least one alcohol.

37. The pharmaceutical composition of claim 36, wherein the pharmaceutical composition comprises about 0.1% to about 5% by weight of the at least one alcohol.

38. The pharmaceutical composition of any one of claims 29-37, further comprising at least one emollient or humectant.

39. The pharmaceutical composition of claim 38, wherein the pharmaceutical composition comprises about 0.1% to about 65% by weight of the at least one emollient or humectant.

40. The pharmaceutical composition of claim 38 or 39, wherein the at least one emollient or humectant is chosen from glycerin, propylene glycol, and combinations thereof.

41. The pharmaceutical composition of any one of claims 29-40, further comprising at least one vehicle.

42. The pharmaceutical composition of claim 29, wherein the pharmaceutical composition comprises:

about 1% to about 45% by weight of oleic acid;
about 0.1% to about 20% by weight of glycerin;
about 0.1% to about 45% by weight of propylene glycol;
about 0.1% to about 5% by weight of benzyl alcohol;
about 0.1% to about 5% by weight of a Pemulen™ polymer;

an amount of 10% (w/w) sodium hydroxide solution sufficient to adjust the pH to a value in the range of about 4 to about 6; and

Q.S. to 100 of purified water.

43. The pharmaceutical composition of any one of claims 1-42, wherein the pharmaceutical composition comprises about 0.1% to about 10% by weight of the at least one compound.

44. The pharmaceutical composition of any one of claims 1-43, wherein the pharmaceutical composition comprises at least about 0.5% by weight of the at least one compound.

45. The pharmaceutical composition of any one of claims 1-44, wherein the pharmaceutical composition comprises about 1% by weight of the at least one compound.

46. The pharmaceutical composition of any one of claims 1-44, wherein the pharmaceutical composition comprises about 2% by weight of the at least one compound.

47. The pharmaceutical composition of any one of claims 1-46, wherein at least about 95% by weight of the at least one compound is (R)-2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile.

48. The pharmaceutical composition of any one of claims 1-47, wherein at least about 95% by weight of the at least one compound is an (E) isomer.

49. The pharmaceutical composition of claim 47 or 48, wherein the at least one compound is substantially amorphous.

50. The pharmaceutical composition of any one of claims 47-49, wherein the at least one compound is micronized.

51. The pharmaceutical composition of claim 50, wherein the at least one compound has a particle size distribution D_{90} in the range of about 5 to about 10 microns.

52. The pharmaceutical composition of any one of claims 1-48, wherein the at least one compound is crystalline.

53. The pharmaceutical composition of claim 52, wherein the at least one compound is crystalline Form (I).

54. The pharmaceutical composition of claim 53, wherein crystalline Form (I) is characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 6.3 ± 0.2, 12.6 ± 0.2, 16.2 ± 0.2, 17.6 ± 0.2, 18.2 ± 0.2, 18.4 ± 0.2, and 22.1 ± 0.2.

55. The pharmaceutical composition of claim 52, wherein the at least one compound is crystalline Form (II).

56. The pharmaceutical composition of claim 55, wherein crystalline Form (II) is characterized by an X-ray powder diffractogram having a signal at at least three two-theta values chosen from 6.3 ± 0.2, 15.2 ± 0.2, 16.0 ± 0.2, 16.6 ± 0.2, 17.7 ± 0.2, 20.0 ± 0.2, 24.8 ± 0.2, and 27.5 ± 0.2.

57. A method of treating a dermatological disorder in a mammal in need thereof, the method comprising topically administering to at least a portion of the skin of the subject of the mammal at least one topical pharmaceutical composition of to any one of claims 1-56.

58. The method of claim 57, wherein the dermatological disorder is chosen from pemphigus vulgaris, pemphigus foliaceus, cutaneous lupus, cutaneous lupus erythematosus, dermatitis, discoid lupus, atopic dermatitis, bullous pemphigoid, drug related skin reaction, chronic idiopathic urticaria, chronic spontaneous urticaria, symptomatic dermographism, alopecia, alopecia areata, vitiligo, pyoderma gangrenosum, membrane pemphigoid, epidermolysis bullosa acquisita, Steven Johnson Syndrome, TEN Toxic epidermal necrolysis, drug eruptions, folliculitis decalvans, pseudofolliculitis barbae, leukocytoclastic vasculitis,

hidradenitis suppurativa, palmar plantar pustulosis, Lichenoid dermatitis, dermatitis herpetiformis, rosacea, erythema of rosacea, papulopustular rosacea, neutrophilic dermatoses, chronic kidney disease associated pruritis, end stage renal disease induced pruritis, acne, mycosis fungoides, and sweet syndrome in a mammal in need thereof.

59. The method of claim 57 or 58, wherein the dermatological disorder is pemphigus vulgaris or pemphigus foliaceus.

60. The method of claim 57 or 58, wherein the dermatological disorder is atopic dermatitis.

61. The method of any one of claims 57-60, wherein the mammal is a human.